PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30642543-11 2019 Cetuximab can potentially increase the efficacy of afatinib or osimertinib in NSCLC with EGFR exon 20 insertion mutations. osimertinib 63-74 epidermal growth factor receptor Mus musculus 89-93 27439477-1 2016 Osimertinib (AZD9291) is a potent, selective, irreversible inhibitor of EGFR-sensitizing (exon 19 and L858R) and T790M-resistant mutation. osimertinib 13-20 epidermal growth factor receptor Mus musculus 72-76 34464874-1 2021 The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to osimertinib in the treatment of non-small cell lung cancer (NSCLC). osimertinib 85-96 epidermal growth factor receptor Mus musculus 39-43 34826601-2 2022 Osimertinib is the first third-generation EGFR-tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and those resistant to earlier generation EGFR-TKIs due to a T790M mutation. osimertinib 0-11 epidermal growth factor receptor Mus musculus 42-46 34826601-2 2022 Osimertinib is the first third-generation EGFR-tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and those resistant to earlier generation EGFR-TKIs due to a T790M mutation. osimertinib 0-11 epidermal growth factor receptor Mus musculus 160-164 34826601-2 2022 Osimertinib is the first third-generation EGFR-tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and those resistant to earlier generation EGFR-TKIs due to a T790M mutation. osimertinib 0-11 epidermal growth factor receptor Mus musculus 217-221 34826601-5 2022 Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction. osimertinib 51-62 epidermal growth factor receptor Mus musculus 166-170 34826601-5 2022 Here, we report that berberine, when combined with osimertinib, synergistically and selectively decreased the survival of several MET-amplified osimertinib-resistant EGFR mutant NSCLC cell lines with enhanced induction of apoptosis likely through Bim elevation and Mcl-1 reduction. osimertinib 144-155 epidermal growth factor receptor Mus musculus 166-170 34464874-5 2021 When tested in Ba/F3 cells expressing EGFRL858R/T790M/C797S, compound 11 resulted significantly more potent than osimertinib at inhibiting both EGFR autophosphorylation and proliferation, even if the inhibition of EGFR autophosphorylation by compound 11 in Ba/F3 cells was not long lasting. osimertinib 113-124 epidermal growth factor receptor Mus musculus 144-148 34855271-1 2022 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib 64-75 epidermal growth factor receptor Mus musculus 49-53 34855271-1 2022 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib 64-75 epidermal growth factor receptor Mus musculus 97-101 34855271-1 2022 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib 64-75 epidermal growth factor receptor Mus musculus 147-151 34855271-5 2022 Meanwhile, LS-106 exhibited comparable kinase inhibitory effect to osimertinib on EGFRL858R/T790M and wild-type EGFR. osimertinib 67-78 epidermal growth factor receptor Mus musculus 112-116 34491761-1 2021 The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including osimertinib, have been approved for clinical use. osimertinib 212-223 epidermal growth factor receptor Mus musculus 38-42 34491761-1 2021 The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including osimertinib, have been approved for clinical use. osimertinib 212-223 epidermal growth factor receptor Mus musculus 173-177 33986687-2 2021 Both SH-1028 and osimertinib have a pyrimidine structure (a typical mutant-selective EGFR TKI structure). osimertinib 17-28 epidermal growth factor receptor Mus musculus 85-89 34145930-4 2021 We induced osimertinib resistance in a mouse model of LMC using an EGFR-mutant NSCLC cell line (PC9) via continuous oral osimertinib treatment and administration of established resistant cells and examined the resistance mechanism using next-generation sequencing. osimertinib 11-22 epidermal growth factor receptor Mus musculus 67-71 34145930-9 2021 These findings suggest a potential novel therapy against KRAS-G12V-harboring osimertinib-resistant LMC in EGFR-mutant NSCLC. osimertinib 77-88 epidermal growth factor receptor Mus musculus 106-110 34087353-2 2021 However, acquired resistance to mutant EGFR (T790M) can evolve following osimertinib treatment. osimertinib 73-84 epidermal growth factor receptor Mus musculus 39-43 34087353-4 2021 Here, we found that heme levels were increased in osimertinib resistant EGFR-mutant NSCLC cell lines and plasma heme levels were also elevated in osimertinib-treated EGFR-mutant NSCLC patients. osimertinib 50-61 epidermal growth factor receptor Mus musculus 72-76 34087353-4 2021 Here, we found that heme levels were increased in osimertinib resistant EGFR-mutant NSCLC cell lines and plasma heme levels were also elevated in osimertinib-treated EGFR-mutant NSCLC patients. osimertinib 146-157 epidermal growth factor receptor Mus musculus 166-170 34087353-6 2021 DHA downregulated the expression of heme oxygenase 1 and inhibited cell proliferation in osimertinib-resistant EGFR-mutant NSCLC cells (PC9-GR4-AZD1), which was further enhanced by addition of 5-aminolevulinic acid, protoporphyrin IX and hemin. osimertinib 89-100 epidermal growth factor receptor Mus musculus 111-115 34087353-8 2021 Combination treatment with osimertinib and DHA also increased the levels of ROS, downregulated the phosphorylation or protein levels of several RTKs that often are overexpressed in osimertinib-resistant EGFR-mutant NSCLC cells, and inhibited tumor growth without toxicity in a PC9-GR4-AZD1 xenograft mouse model. osimertinib 27-38 epidermal growth factor receptor Mus musculus 203-207 34087353-8 2021 Combination treatment with osimertinib and DHA also increased the levels of ROS, downregulated the phosphorylation or protein levels of several RTKs that often are overexpressed in osimertinib-resistant EGFR-mutant NSCLC cells, and inhibited tumor growth without toxicity in a PC9-GR4-AZD1 xenograft mouse model. osimertinib 181-192 epidermal growth factor receptor Mus musculus 203-207 34087353-9 2021 The results suggest that DHA is able to reverse the resistance to osimertinib in EGFR-mutant NSCLC by elevating ROS level and impair heme metabolism. osimertinib 66-77 epidermal growth factor receptor Mus musculus 81-85 33993094-0 2021 Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. osimertinib 7-18 epidermal growth factor receptor Mus musculus 35-39 34439260-2 2021 In this study, we focused on the association of ANXA1 and chemosensitivity with a third generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), Osimertinib, in lung cancer cells with EGFR mutations. osimertinib 170-181 epidermal growth factor receptor Mus musculus 159-163 34439260-6 2021 Further study showed that the knockdown of ANXA1 inhibited the phosphorylation of EGFR and down-stream Akt pathways and promoted apoptosis in lung cancer cells treated with Osimertinib. osimertinib 173-184 epidermal growth factor receptor Mus musculus 82-86 34298655-0 2021 Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. osimertinib 109-120 epidermal growth factor receptor Mus musculus 68-72 35447433-1 2022 The C797S mutation in EGFR is a leading mechanism of clinically acquired resistance against osimertinib for non-small cell lung cancer (NSCLC). osimertinib 92-103 epidermal growth factor receptor Mus musculus 22-26 33049499-0 2020 Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. osimertinib 127-138 epidermal growth factor receptor Mus musculus 63-67 33028591-1 2021 Purpose Osimertinib is a potent and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. osimertinib 8-19 epidermal growth factor receptor Mus musculus 106-110 33049499-1 2020 OBJECTIVES: The emergence of acquired resistance to the third generation EGFR inhibitor, osimertinib (AZD9291 or TAGRISSO ), is an unavoidable huge clinical challenge. osimertinib 89-100 epidermal growth factor receptor Mus musculus 73-77 33049499-1 2020 OBJECTIVES: The emergence of acquired resistance to the third generation EGFR inhibitor, osimertinib (AZD9291 or TAGRISSO ), is an unavoidable huge clinical challenge. osimertinib 102-109 epidermal growth factor receptor Mus musculus 73-77 33049499-1 2020 OBJECTIVES: The emergence of acquired resistance to the third generation EGFR inhibitor, osimertinib (AZD9291 or TAGRISSO ), is an unavoidable huge clinical challenge. osimertinib 113-121 epidermal growth factor receptor Mus musculus 73-77 33049499-8 2020 RESULTS: Inhibition of ACK1 with the novel ACK1 inhibitor, (R)-9b synergized with osimertinib in inhibiting the growth of EGFR mutant NSCLC cell lines. osimertinib 82-93 epidermal growth factor receptor Mus musculus 122-126 33049499-12 2020 Further, the (R)-9b and osimertinib combination was also effective in inhibiting the growth of EGFR mutant NSCLC cell lines with acquired resistance to osimertinib, which possess elevated levels of ACK1, and the growth of osimertinib-resistant tumors in vivo. osimertinib 24-35 epidermal growth factor receptor Mus musculus 95-99 33049499-12 2020 Further, the (R)-9b and osimertinib combination was also effective in inhibiting the growth of EGFR mutant NSCLC cell lines with acquired resistance to osimertinib, which possess elevated levels of ACK1, and the growth of osimertinib-resistant tumors in vivo. osimertinib 152-163 epidermal growth factor receptor Mus musculus 95-99 33049499-0 2020 Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. osimertinib 127-138 epidermal growth factor receptor Mus musculus 111-115 31254668-9 2019 RESULTS: Modeling suggested that EGFR M766Q could disrupt osimertinib binding. osimertinib 58-69 epidermal growth factor receptor Mus musculus 33-37 32659740-0 2020 Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. osimertinib 0-11 epidermal growth factor receptor Mus musculus 25-29 31821539-9 2020 Moreover, the combination of an MEK or ERK inhibitor with a first-generation (eg, erlotinib) or second-generation (eg, afatinib) EGFR-TKI also very effectively inhibited the growth of osimertinib-resistant cells in vitro and of tumors in vivo, although these cell lines were cross-resistant to first-generation or second-generation EGFR-TKIs. osimertinib 184-195 epidermal growth factor receptor Mus musculus 129-133 31821539-9 2020 Moreover, the combination of an MEK or ERK inhibitor with a first-generation (eg, erlotinib) or second-generation (eg, afatinib) EGFR-TKI also very effectively inhibited the growth of osimertinib-resistant cells in vitro and of tumors in vivo, although these cell lines were cross-resistant to first-generation or second-generation EGFR-TKIs. osimertinib 184-195 epidermal growth factor receptor Mus musculus 332-336 31999837-0 2020 Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). osimertinib 110-121 epidermal growth factor receptor Mus musculus 34-66 31999837-0 2020 Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). osimertinib 135-146 epidermal growth factor receptor Mus musculus 34-66 31791326-15 2019 Combination of PTK2 inhibitor and EGFR-TKI (defactinib and osimertinib) recovered EGFR-TKI sensitivity in the EGFR-TKI-resistant NSCLC. osimertinib 59-70 epidermal growth factor receptor Mus musculus 34-38 31791326-15 2019 Combination of PTK2 inhibitor and EGFR-TKI (defactinib and osimertinib) recovered EGFR-TKI sensitivity in the EGFR-TKI-resistant NSCLC. osimertinib 59-70 epidermal growth factor receptor Mus musculus 82-86 32873635-3 2020 Consistent with our previous studies, we show here that long-term, moderate hypoxia promotes resistance to the EGFR TKI osimertinib (AZD9291) in the NSCLC cell line H1975, which harbors two EGFR mutations including T790M. osimertinib 120-131 epidermal growth factor receptor Mus musculus 111-115 32873635-3 2020 Consistent with our previous studies, we show here that long-term, moderate hypoxia promotes resistance to the EGFR TKI osimertinib (AZD9291) in the NSCLC cell line H1975, which harbors two EGFR mutations including T790M. osimertinib 133-140 epidermal growth factor receptor Mus musculus 111-115 33064977-0 2020 LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway. osimertinib 45-56 epidermal growth factor receptor Mus musculus 30-34 33064977-0 2020 LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway. osimertinib 45-56 epidermal growth factor receptor Mus musculus 110-114 33064977-8 2020 TSLNC8 overexpression or osimertinib administration led to promotion of apoptosis and inhibition of cell proliferation, migration and invasion, as well as deactivation of the EGFR-STAT3 pathway, whereas TSLNC8 knockdown had opposite effects. osimertinib 25-36 epidermal growth factor receptor Mus musculus 175-179 33064977-12 2020 In this study, we revealed a TSLNC8-EGFR-STAT3 signaling axis in lung cancer, and TSLNC8 overexpression significantly enhanced the anti-tumor effects of osimertinib via inhibiting EGFR-STAT3 signaling. osimertinib 153-164 epidermal growth factor receptor Mus musculus 36-40 33064977-12 2020 In this study, we revealed a TSLNC8-EGFR-STAT3 signaling axis in lung cancer, and TSLNC8 overexpression significantly enhanced the anti-tumor effects of osimertinib via inhibiting EGFR-STAT3 signaling. osimertinib 153-164 epidermal growth factor receptor Mus musculus 180-184 32510788-3 2020 DDC-01-163 is also effective against osimertinib-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations. osimertinib 37-48 epidermal growth factor receptor Mus musculus 94-98 32510788-4 2020 When combined with an ATP-site EGFR inhibitor, osimertinib, the anti-proliferative activity of DDC-01-163 against L858R/T790M EGFR-Ba/F3 cells is enhanced. osimertinib 47-58 epidermal growth factor receptor Mus musculus 126-130 32497272-7 2020 RESULTS: Osimertinib combined with an MEK or ERK inhibitor synergistically decreased cell survival with enhanced induction of apoptosis in EGFR-mutant NSCLC cells but not in EGFR wild-type NSCLC cells. osimertinib 9-20 epidermal growth factor receptor Mus musculus 139-143 32631532-2 2020 EGFR19D/T790M/C797S mutation is one of the primary reasons for the emergence of resistance after treatment with the third-generation EGFR inhibitors such as AZD9291, CO1686 and Olmutinib. osimertinib 157-164 epidermal growth factor receptor Mus musculus 0-4 32354888-2 2020 We compared the efficacy of two EGFR-tyrosine kinase inhibitors (TKIs), erlotinib and osimertinib on a PC-9-GFP EGFR mutant NSCLC growing in the brain of nude mice. osimertinib 86-97 epidermal growth factor receptor Mus musculus 112-116 32354888-6 2020 CONCLUSION: This study strongly supports the high activity of osimertinib for intracranial lesions of EGFR-mutant NSCLC. osimertinib 62-73 epidermal growth factor receptor Mus musculus 102-106 31678994-7 2020 We therefore treated mice with orthotopic xenografts using the 3rd-generation EGFR inhibitor osimertinib, with or without STAT3 knockdown. osimertinib 93-104 epidermal growth factor receptor Mus musculus 78-82 31563735-14 2019 Our findings indicate that osimertinib, rather than gefitinib combined with anti-PD-L1 treatment could lead to lung injury in an EGFR mutated tumor-bearing mouse model. osimertinib 27-38 epidermal growth factor receptor Mus musculus 129-133 31254668-13 2019 CONCLUSIONS: Acquisition of EGFR M766Q exon 20 mutation is a novel mechanism of acquired resistance to osimertinib. osimertinib 103-114 epidermal growth factor receptor Mus musculus 28-32 31254668-14 2019 EGFR-mutant lung cancers with an acquired EGFR M766Q mutation in the setting of osimertinib resistance may be sensitive to neratinib and poziotinib. osimertinib 80-91 epidermal growth factor receptor Mus musculus 0-4 31254668-14 2019 EGFR-mutant lung cancers with an acquired EGFR M766Q mutation in the setting of osimertinib resistance may be sensitive to neratinib and poziotinib. osimertinib 80-91 epidermal growth factor receptor Mus musculus 42-46 31314158-4 2019 Among these EGFR variants, we report that an exon 20 deletion/insertion mutation S768insVGH is resistant to erlotinib (a first-generation TKI), but sensitive to osimertinib (a third-generation TKI). osimertinib 161-172 epidermal growth factor receptor Mus musculus 12-16 31108249-11 2019 In addition, osimertinib-resistant cells were established by stepwise exposure to osimertinib and harbored EGFR E762K mutation. osimertinib 13-24 epidermal growth factor receptor Mus musculus 107-111 31108249-12 2019 CONCLUSIONS: Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclinical models. osimertinib 13-24 epidermal growth factor receptor Mus musculus 43-47 30807997-1 2019 The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). osimertinib 76-83 epidermal growth factor receptor Mus musculus 105-137 30807997-1 2019 The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). osimertinib 76-83 epidermal growth factor receptor Mus musculus 203-207